Acute Heart Failure SyndromeNCT06967441
Respiratory Virus Infections in Acute Heart Failure
An observational study of Acute Heart Failure Syndrome, run by Minjae Yoon at 3 sites in South Korea.
Trial summary
Patients admitted to the cardiology department with acute heart failure who have a nasopharyngeal respiratory virus PCR test performed within 72 hours of admission will be enrolled in the study cohort. The detection rate of respiratory viruses including influenza virus, RSV, and coronavirus will be analysed. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Acute Heart Failure Syndrome
- How many people
- 360 participants
- Where
- 3 sitesSouth Korea
- Study dates
- 7 Apr 2025to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- Adult, Older adult
Study population: Patients hospitalised with AHF at three healthcare facilities who had respiratory virus PCR testing performed
Who may be able to join
- Adult aged 19 years or older admitted to the cardiology department with acute heart failure
- NT-proBNP >300 pg/mL
- Clinician judgement of possible respiratory viral infection (fever >38 degrees or cough, respiratory symptoms such as sputum or consolidation on x-ray or CRP >5 mg/dL)
- Patients who have a nasopharyngeal swab for respiratory virus PCR test performed within 72 hours of admission for any of the 3 reasons
Who cannot join
- Patients with a clear other cause of acute heart failure (ex. ACS, bradycardia requiring a pacemaker, uncontrolled tachycardia, uncontrolled severe hypertension (SBP >180mmHg or DBP >110mmHg), haemoglobin <7g/dL or AHF precipitated by medication non-adherence)
- If the cause of pulmonary oedema is prominently attributed to exacerbation of CKD
- If there is a clear other source of infection that can explain the fever
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea3 sites, 3 recruiting
- Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620
Minjae Yoon, MD, minjae1677@gmail.com
- Recruiting
Samsung medical center
Seoul
Darae Kim, daraekyrie@gmail.com
- Recruiting
Seoul ST. Mary's Hospital
Seoul
Jong-Chan Youn, +82-10-8762-5683, jong.chan.youn@gmail.com
About this study
Official title: Respiratory Virus Infections in Hospitalized Patients With Acute Heart Failure Syndrome: A Prospective Multi-center Observational Study
Patients admitted to the cardiology department with acute heart failure who have a nasopharyngeal respiratory virus PCR test performed within 72 hours of admission will be enrolled in the study cohort.
The detection rate of respiratory viruses including influenza virus, RSV, and coronavirus will be analysed. The investigators will also look for seasonal changes in the frequency of respiratory viruses and differences in the clinical presentation of heart failure based on respiratory virus infection.
- Conditions
- Acute Heart Failure Syndrome
- Keywords
- acute heart failure, respiratory virus
What is being measured
The primary outcome is the main question the study is designed to answer.
Respiratory virus PCR detection rate
Respiratory virus PCR detection rate (especially RSV, influenza virus) in acute HF
Measured: Within 3 days of admission
Secondary outcomes (5)
Days of hospitalization
Days of hospitalization
Measured: From admission to discharge during index hospitalization (upto 30 days)
Rate of ICU care or ventilation
Rate of ICU care or ventilation
Measured: From admission to discharge during index hospitalization (upto 30 days)
In hospital mortality
In hospital mortality
Measured: From admission to discharge during index hospitalization (upto 30 days)
mortality
after discharge, 12-month mortality
Measured: 12 month
Rehospitalization
after discharge, 12-month rehospitalization
Measured: 12month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2025
- Study start7 Apr 2025
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Heart Failure SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 360 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Minjae Yoon
- Sponsor type
- University, hospital or other
- Collaborators
- Samsung Medical Center, Seoul St. Mary's Hospital
- Responsible party
- Sponsor-investigator, Minjae Yoon, Seoul National University Bundang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06967441
- Sponsor's protocol ID
- SNUBH IRB NO: B-2412-941-302
- Status last verified
- Mar 2026
- First submitted
- 17 Apr 2025
- Last updated
- 11 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Respiratory Virus Infections in Hospitalized Patients With Acute Heart Failure Syndrome: A Prospective Multi-center Observational Study
- ClinicalTrials.gov ID
- NCT06967441
- Acronym / sponsor ID
- SNUBH IRB NO: B-2412-941-302
- Conditions
- Acute Heart Failure Syndrome
- Keywords
- acute heart failure, respiratory virus
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 360 participants (estimated)
- Lead sponsor
- Minjae YoonUniversity, hospital or other
- Collaborators
- Samsung Medical Center, Seoul St. Mary's Hospital
- Study start
- 7 Apr 2025 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 13 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients admitted to the cardiology department with acute heart failure who have a nasopharyngeal respiratory virus PCR test performed within 72 hours of admission will be enrolled in the study cohort.
The detection rate of respiratory viruses including influenza virus, RSV, and coronavirus will be analysed. The investigators will also look for seasonal changes in the frequency of respiratory viruses and differences in the clinical presentation of heart failure based on respiratory virus infection.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients hospitalised with AHF at three healthcare facilities who had respiratory virus PCR testing performed
Key inclusion criteria (4 listed)
- Adult aged 19 years or older admitted to the cardiology department with acute heart failure
- NT-proBNP >300 pg/mL
- Clinician judgement of possible respiratory viral infection (fever >38 degrees or cough, respiratory symptoms such as sputum or consolidation on x-ray or CRP >5 mg/dL)
- Patients who have a nasopharyngeal swab for respiratory virus PCR test performed within 72 hours of admission for any of the 3 reasons
Key exclusion criteria (3 listed)
- Patients with a clear other cause of acute heart failure (ex. ACS, bradycardia requiring a pacemaker, uncontrolled tachycardia, uncontrolled severe hypertension (SBP >180mmHg or DBP >110mmHg), haemoglobin <7g/dL or AHF precipitated by medication non-adherence)
- If the cause of pulmonary oedema is prominently attributed to exacerbation of CKD
- If there is a clear other source of infection that can explain the fever
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Respiratory virus PCR detection rate
Time frame: Within 3 days of admission
Respiratory virus PCR detection rate (especially RSV, influenza virus) in acute HF
5 secondary outcomes
Days of hospitalization
Time frame: From admission to discharge during index hospitalization (upto 30 days)
Rate of ICU care or ventilation
Time frame: From admission to discharge during index hospitalization (upto 30 days)
In hospital mortality
Time frame: From admission to discharge during index hospitalization (upto 30 days)
mortality
Time frame: 12 month
Rehospitalization
Time frame: 12month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Heart Failure Syndrome
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingObservational study
CytOSorb TreatMent Of Critically Ill PatientS Registry
Septic Shock, Acute Respiratory Distress Syndrome
Not yet recruitingObservational study
Right Heart Injury Monitoring on ECMO
Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure (ARF)
RecruitingObservational study
Common Femoral Vein-to-Artery Diameter Ratio for Detection of Elevated LVEDP
Acute Coronary Syndrome, Chronic Coronary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Heart Failure Syndrome, run by Minjae Yoon at 3 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Minjae Yoon, MD (+82-10-6334-1917, minjae1677@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Respiratory virus PCR detection rate (time frame: Within 3 days of admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2026.